Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Bio-Path Holdings, Inc. Bio-Path Holdings Provides Clinical Update and Expansion Plans July 08, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress June 14, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules June 05, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules June 04, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting June 03, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress May 24, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Reports First Quarter 2024 Financial Results May 15, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024 May 08, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules April 19, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules April 18, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients April 18, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Expands Global Patent Portfolio April 15, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Provides 2024 Clinical and Operational Update April 02, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Reports Full Year 2023 Financial Results March 08, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024 March 01, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Announces 1-for-20 Reverse Stock Split February 21, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients January 10, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia December 14, 2023 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Reports Third Quarter 2023 Financial Results November 15, 2023 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023 November 08, 2023 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia October 24, 2023 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference September 08, 2023 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Reports Second Quarter 2023 Financial Results August 15, 2023 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023 August 08, 2023 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering August 03, 2023 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia August 01, 2023 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors July 17, 2023 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings Reports First Quarter 2023 Financial Results May 12, 2023 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023 May 05, 2023 From Bio-Path Holdings, Inc. Via GlobeNewswire Tickers BPTH Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.